96. Crohn disease
2,209 clinical trials,   1,276 drugs   (DrugBank: 240 drugs),   166 drug target genes,   210 drug target pathways

Searched query = "Crohn disease", "Terminal ileitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
5 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02852694
(ClinicalTrials.gov)
February 28, 20179/6/2016Reduce Risk for Crohn's Disease PatientsRisk-stratified Randomized Controlled Trial in Paediatric Crohn Disease:Methotrexate vs Azathioprine or Adalimumab for Maintaining Remission in Patients at Low or High Risk for Aggressive Disease Course, respectively-a Treatment StrategyCrohn's DiseaseDrug: Methotrexate;Drug: Adalimumab;Drug: Azathioprine / 6 MercaptopurinePIBD-NetEuropean CommissionRecruiting6 Years17 YearsAll312Phase 4France
2NCT02413047
(ClinicalTrials.gov)
May 20156/3/2015Evaluate if Response to Infliximab or Adalimumab May be Regained With an ImmunomodulatorA Pilot Study to Evaluate if Response to Infliximab or Adalimumab May be Regained With the Addition of an ImmunomodulatorInflammatory Bowel Disease;Ulcerative Colitis;Crohn's DiseaseDrug: Azathioprine;Drug: 6 mercaptopurine;Drug: MethotrexateIndiana UniversityNULLTerminated18 Years80 YearsAll3N/AUnited States
3NCT01629628
(ClinicalTrials.gov)
July 201219/6/2012Adalimumab for the Management of Post-operative Crohn's Disease (CD)An Investigator Initiated Prospective, Single Center, Randomized, Open Label Study to Assess the Efficacy of Adalimumab for the Maintenance of Remission in Post-operative CD PatientsCrohn DiseaseDrug: Adalimumab;Drug: 6 MercaptopurineTel-Aviv Sourasky Medical CenterAbbottNot yet recruiting18 Years70 YearsBoth100Phase 3Israel
4NCT01094613
(ClinicalTrials.gov)
November 201025/3/2010Multicenter Clinical Efficacy and Safety Study of Delayed Release 6MP in Crohn's DiseaseMultiCTR Randomized Double-Blind Double-Dummy Study to Evaluate Clinical Efficacy/Safety of DR 6MP for Targeted Ileal Delivery vs Purinethol in Patients w/Moderately Active Crohn's DiseaseCrohn's DiseaseDrug: Delayed Release 6 mercaptopurine;Drug: 6 MercaptopurineTeva GTCNULLTerminated18 Years75 YearsBoth70Phase 1;Phase 2Israel
5NCT00774982
(ClinicalTrials.gov)
December 200816/10/2008Pilot Comparative Bioavailability Study of 6Mercaptopurine (Delayed Release vs. Purinethol) in Crohns Disease PatientsPilot, Randomized, Open-Label, Two-Way Crossover Comparative Bioavailability Study of 40 mg Delayed Release Oral 6Mercaptopurine Versus 100 mg Purinethol in Patients With Crohns DiseaseCrohns DiseaseDrug: Delayed Release 6 mercaptopurine;Drug: 6 MercaptopurineTeva GTCNULLCompleted18 Years50 YearsBoth12Phase 1Israel